Cowen & Co. analyst Boris Peaker maintained a Buy rating on Stemline Therapeutics Inc (NASDAQ: STML) today. The company’s shares opened today at $17.70.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.9% and a 53.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics Inc, CytomX Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Stemline Therapeutics Inc is Strong Buy and the average price target is $34, representing a 92.1% upside.
In a report issued on June 12, Roth Capital also initiated coverage with a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.55 and a one-year low of $7.30. Currently, Stemline Therapeutics Inc has an average volume of 299K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.
